<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 40-year-old man developed a <z:hpo ids='HP_0002277'>Horner syndrome</z:hpo> as part of a dorsolateral medullary <z:e sem="disease" ids="C0521542" disease_type="Disease or Syndrome" abbrv="">brainstem infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-six hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of the <z:hpo ids='HP_0001297'>stroke</z:hpo>, topical instillation of 0.5% apraclonidine produced reversal of <z:hpo ids='HP_0009916'>anisocoria</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This is the first case in which apraclonidine testing has been applied to a patient with a <z:hpo ids='HP_0002277'>Horner syndrome</z:hpo> caused by a lesion in the first segment of the oculosympathetic pathway and the shortest reported interval between clinical manifestations of the lesion and apraclonidine-induced reversal of <z:hpo ids='HP_0009916'>anisocoria</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A review of <z:hpo ids='HP_0000001'>all</z:hpo> reported cases of apraclonidine testing in <z:hpo ids='HP_0002277'>Horner syndrome</z:hpo> suggests that this is a promising diagnostic adjunct that must be validated in larger studies </plain></SENT>
</text></document>